Entries by Thomas Gabrielczyk

NuCana raises US$114m in IPO of ADSs

Scotch cancer corp NuCana plc was up 3% (to US$18.61) after closing an initial public offering on Friday led by Citigroup, Jefferies and Cowen and co-managed by William Blair.

Researchers unravel patterns of cancer heterogeneity

Up to recently, it was not possible for academic researchers to visualise the spatial distribution of intratumoural heterogeneity within solid tumours. An international research team has now reported a way to track changes with whole-tissue biospy phenotyping.

Ablynx takes Phase III hurdle in acquired TTP

Belgian nanobody developer Ablynx NV‘s nanobody caplacizumab has met relevant endpoints in the pivotal Hercules Phase III study in patients with thrombotic thrombocytopenic purpura (aTTP),  paving the way to market authorisation in Europe and the US.

Dipstick test detects Zika

A newly-developed, fast, and cost-effective dipstick test sensitively and specifically identified Zika virus and all four dengue virus subtypes without any detectable cross-reactivity. 

Why to watch out Spain

The Spanish biotech sector is growing. This attracts more and more international investors. End of September ASEBIO organised the first edition of an Investor Day. 

Newron raises CHF27m

Neurology specialist Newron Pharmaceuticals S.p.A. (Milan) has raised gross proceeds of CHF 27m through a private placement of new shares via an accelerated book-building process.